Avaleht › Südamepuudulikkus › Washington › Seattle
Südamepuudulikkus kliinilised uuringud linnas Seattle, WA
17 uuringut haiguse Südamepuudulikkus jaoks otsivad osalejaid linnas Seattle ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
VärbamineFaas 3
- Virginia Mason Medical Center, Seattle
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
VärbamineFaas 2
- Local Institution - 132, Seattle
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
VärbamineFaas 2/3
- Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019), Seattle
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
VärbamineFaas 2
- Swedish Heart & Vascular Institute, Advanced Cardiac Support Program, Seattle
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
VärbamineVaatlusuuring
- Virginia Mason Medical Center, Seattle
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
VärbamineFaas 3
- Tenax Investigational Site, Seattle
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
VärbamineFaas 3
- Swedish Medical Center_Seattle, Seattle
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
VärbamineFaas 2
- Seattle Children's Hospital, Seattle
Assessment of CCM in HF With Higher Ejection Fraction
Värbamine
- Swedish Medical Center, Seattle
Repurposing Valsartan May Protect Against Pulmonary Hypertension
VärbamineFaas 2
- University of Washington Medical Center, Seattle
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
VärbamineFaas 3
- University of Washington, Seattle
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
Värbamine
- University of Washington Medical Center, Seattle
Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV
Värbamine
- University of Washington, Seattle
Left vs Left Randomized Clinical Trial
Värbamine
- University of Washington, Seattle
Cardiogenic Shock Working Group Registry
VärbamineVaatlusuuring
- University of Washington Medical Center, Seattle
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
VärbamineFaas 1/2
- University of Washington Medicine, Seattle
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
Värbamine
- University of Washington Medical Center, Seattle
Südamepuudulikkus uuringud teistes linnades
- New York City, NY51 uuringut
- Boston, MA44 uuringut
- Dallas, TX42 uuringut
- Houston, TX36 uuringut
- Cleveland, OH33 uuringut
- Chicago, IL31 uuringut
- Philadelphia, PA31 uuringut
- San Francisco, CA29 uuringut
- St. Louis, MO26 uuringut
- Durham, NC26 uuringut
- Kansas City, MO25 uuringut
- Atlanta, GA25 uuringut
Muud uuringud linnas Seattle
- Mitteväikerakuline kopsuvähk53 uuringut
- Vähk (kõik liigid)49 uuringut
- Eesnäärmevähk42 uuringut
- Äge müeloidne leukeemia40 uuringut
- Rinnavähk39 uuringut
- Metastaatiline vähk39 uuringut
- Käär- ja pärasoolevähk34 uuringut
- Kopsuvähk33 uuringut
- Munasarjavähk30 uuringut
- Müeloom22 uuringut
- Müelodüsplastilised sündroomid21 uuringut
- Äge lümfoblastne leukeemia21 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.